Table 3.
Comparison of clinical background between the AEg and the on‐AEg
| AEg (n = 18) | Non‐AEg (n = 37) | P‐value | |
|---|---|---|---|
| Median age (range) | 69 (45–79) | 71 (48–82) | 0.524 |
| Sex | |||
| Male | 17 | 31 | 0.406 |
| Female | 1 | 6 | |
| Brinkman index, median (range) | 1010 (62–2400) | 1000 (0–2400) | 0.836 |
| Histology | |||
| Squamous | 5 | 15 | 0.391 |
| Nonsquamous | 13 | 22 | |
| ECOG PS | |||
| 0 or 1 | 16 | 29 | 0.470 |
| 2 | 2 | 8 | |
| PD‐L1(%)†, median (range) | 65 (0–100) | 20 (0–100) | 0.175 |
| Best overall response | |||
| CR/PR (ORR %) | 9 (50.0%) | 3 (8.1%) | 0.001 |
| SD/PD/NE | 9 | 34 | |
| CR/PR/SD (DCR %) | 17 (94.4%) | 14 (37.8%) | <0.001 |
| PD/NE | 1 | 23 | |
| Treatment duration (days), median (range) | 98 (14–263) | 46 (0–384) | 0.798* |
*
Log‐rank test.
†
Evaluable cases only.
CR, complete response; DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group; NE, not evaluable; ORR, overall response rate; PD‐L1, programmed death‐ligand 1; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease; Sq.